Optimal Sequence of Implied Modalities in the Adjuvant Setting of Breast Cancer Treatment: An Update on Issues To Consider
Authors:
- Pelagia G. TsoutsouPTPelagia G. Tsoutsou
- Joseph GligorovJGJoseph Gligorov
- on behalf of the Association of Radiotherapy and Oncology in the Mediterranean area (AROME)O(on behalf of the Association of Radiotherapy and Oncology in the Mediterranean area (AROME)
- 1 November 2010
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (11) , 1169-1178
Abstract
The adjuvant setting of early breast cancer treatment is an evolving field where different modalities must be combined to improve outcomes; moreover, quality of life of breast cancer survivors emerges as a new important parameter to consider, thus implying a better understanding of toxicities of these modalities. We have conducted a review focusing on the latest literature of the past 3 years, trying to evaluate the existing data on the maximum acceptable delay of radiotherapy when given as sole adjuvant treatment after surgery and the optimal sequence of all these modalities with respect to each other. It becomes evident radiotherapy should be given as soon as possible and within a time frame of 6–20 weeks. Chemotherapy is given before radiotherapy and hormone therapy. However, radiotherapy should be started within 7 months after surgery in these cases. Hormone therapy with tamoxifen might be given safely concomitantly or sequentially with radiotherapy although solid data are still lacking. The concurrent administration of letrozole and radiotherapy seems to be safe, whereas data on trastuzumab can imply only that it is safe to use concurrently with radiotherapy. Randomized comparisons of hormone therapy and trastuzumab administration with radiotherapy need to be performed.Keywords
This publication has 93 references indexed in Scilit:
- Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomyCancer Treatment Reviews, 2010
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2009
- Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinomaBritish Journal of Cancer, 2009
- Évaluation monocentrique de la tolérance de l’association concomitante de trastuzumab et de radiothérapieCancer/Radiothérapie, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?The Lancet Oncology, 2009
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The Sequencing of Chemotherapy and Radiation Therapy after Conservative Surgery for Early-Stage Breast CancerNew England Journal of Medicine, 1996